Today, the National Growth Fund announced that PharmaNL has met the conditions to convert the conditional allocation of €78.8 million into a definitive grant.
“We at PharmaNL are delighted with this news. Together with stakeholders, we can now begin implementing the ambitions of PharmaNL,” said Brigitte Drees, Director of Pivot Park.
Click here to view the official announcement from the Dutch government.
PharmaNL is a national public-private consortium comprising Leiden University Medical Center, Leiden University, Campus Groningen, and Pivot Park, working closely with FAST - Platform to Future Affordable Sustainable Therapies.
PharmaNL is kicking off with €80 million in funding from the National Growth Fund to invest in research facilities and human capital.
Source: PharmaNL
